To assess the effect of diet enrichment with L-arginine or supplementation at high doses on physiological adaptation during exercise, 9 athletes followed 3 different diets, each over 3 consecutive days, with a wash-out period of 4 d between training sessions: control diet (CD), 5.5 ± 0.3 g/d of L-arginine; Diet 1 (rich in L-arginine food), 9.0 ± 1.1 g/d of L-arginine; and Diet 2 (the same as CD but including an oral supplement of 15 g/d), 20.5 ± 0.3 g/d of L-arginine. Plasma nitrate levels of each participant were determined on the day after each treatment. Participants performed a submaximal treadmill test (initial speed 10-11 km/hr, work increments 1 km/hr every 4 min until 85-90% VO 2max , and passive recovery periods of 2 min). Oxygen uptake and heart rate were monitored throughout the test. Blood lactate concentration ([La -] b ) was determined at the end of each stage. Repeated-measures ANOVA and paired Student's t tests were used to compare the various physiological parameters between diets. The level of significance was set at p < .05. [La -] b showed a significant effect at the 5-min time point between CD and Diet 2 (CD 3.0 ± 0.5 mM, Diet 2 2.5 ± 0.5 mM, p = .03), but this tendency was not found at higher exercise intensities. No significant differences were observed in any of the cardiorespiratory or plasma nitrate levels. In conclusion, dietary L-arginine intake on the days preceding the test does not improve physiological parameters during exercise.
local hypoxia (Vallance, Leone, Calver, Collier, & Moncada, 1992) . In physiological adaptation to exercise, NO plays an important regulatory role by increasing blood flow to the muscles and modulating muscle contraction and glucose uptake (McConell & Kingwell, 2006) . It is also involved in controlling cellular respiration through interaction with enzymes of the mitochondrial respiratory chain (Moncada & Erusalimsky, 2002) , and it may act as an antioxidant in certain situations (Brune et al., 1997) .
During exercise, oxygen consumption (VO 2 ; i.e., total energetic cost of the physical work) is an important parameter that reflects both mechanical efficiency and running performance until fatigue. The inhibition of NO synthesis by endogenous inhibitors such as N G -nitro-L-arginine methyl ester and N G -monomethyl-Larginine has been associated with increased submaximal VO 2 levels in animals during exercise independent of the reduction in blood flow (Shen et al., 1995) . This finding has also been reported in studies both in vitro (Brown, 1995) and in humans (Schrage, Joyner, & Dinenno, 2004) . The increase in VO 2 during NOS blockage has been attributed to the fact that NO affects tissue respiration by reversible inhibition of the respiratory enzyme cytochrome c oxidase (Brown & Cooper, 1994) . Other authors have related the increased VO 2 during NOS blockage to an inhibiting effect of NO on proton leakage over the mitochondrial membrane (Bohuslavs'kyi, Dmytriieva, & Sahach, 2005) . Increases in VO 2 have been associated with decreased mechanical and energetic efficiency during physical effort (Jones, Wilkerson, & Campbell, 2004) . Nevertheless, few attempts have been made to study the effect of exogenous NO delivery on physiological efficiency (VO 2 ) during exercise. Studies with pharmacological NO donors such as nitroprusside and nitroglycerine have shown divergent results: decreases in VO 2 (Loke et al., 1999 ), no effect (Nuñez et al., 2005) , or increases (De Backer et al., 1996) .
The effect of L-arginine on exercise capacity and NO metabolism in healthy participants and highly trained athletes is still not clear (Abel et al., 2005) . The first investigations on oral supplementation with arginine aspartate or arginine glutamate suggested that they could reduce blood lactate concentration ([La -] b ) and accumulation of ammonia after high-intensity exercise. These metabolites have been shown to be involved in the development of muscle fatigue caused by increased muscle acidity (Denis et al., 1991) . However, the role of arginine in these studies may have been masked by the other components that might also contribute to delaying fatigue. In another study, oral arginine aspartate failed to produce metabolic benefit in endurance runners during 14 days of supplementation (Colombani et al., 1999) .
To our knowledge, the dietary intervention of L-arginine intake in athletes has not been studied to date. We hypothesized that a diet rich in L-arginine and/ or higher doses of this amino acid supplement might improve exercise economy in highly trained athletes. The aim of the current study was to determine whether increases in L-arginine intake increase NO delivery and optimize performance (i.e., reduce VO 2 and/or [La - ] b values) during treadmill exercise in athletes.
Methods

Participants
Nine highly trained national-level male tennis players (age 18.2 ± 3.7 years, VO 2peak 57.4 ± 3.9 ml · kg −1 · min −1 , body weight 67.7 ± 8.7 kg, body-mass index 22.0 ± 1.9 kg/m 2 , sum of six skinfolds [triceps, subscapular, supraspinal, abdominal, medial calf, and front thigh] 65.5 ± 12.1 mm) participated in this study. The protocol was approved by the ethics committee of the Sant Cugat High Performance Center (CAR) in Barcelona, and all participants gave their written consent before participation. Exclusion criteria were the presence of cardiovascular disease or any medical treatment. The study was carried out during the early preseason training period. All the tests and analyses were performed in the Exercise Physiology and Nutrition Laboratories of the CAR.
Dietary Intervention
Three diets were designed: control diet (CD), a balanced composition of macronutrients (5.5 ± 0.3 g L-arginine; Maughan, Burke, & Coyle, 2004) ; Diet 1, the same as CD but enriched as much as possible without unbalancing the composition of macronutrients with foods high in L-arginine (9.1 ± 1.1 g L-arginine; Table  1) ; and Diet 2, the same as CD but further including an oral supplement of 5 g of L-arginine (Arginaid, Novartis, ref. 40285) three times per day (20.5 ± 0.3 g L-arginine). Sodium intake was set at a constant level (about 160 mol/day). The energy contents of the macronutrients and L-arginine (Table 1) in each diet were calculated using the software Fuel 3.0 (Human Kinetics, Champaign, IL, USA).
Experimental Intervention
The experiment was conducted over a period of 18 days, during which the participants were administered the three different randomized treatments (CD, Diet 1, and Diet 2). Participants had four meals every day (breakfast, lunch, afternoon snack, and dinner). Each treatment involved 3 days of controlled diet consumption, followed by a day of passive rest when individuals underwent blood sampling and cardiopulmonary exercise testing in the laboratory. A 4-day wash-out period was scheduled before the following stage of the experiment while participants continued with their normal training. This time has been shown to be sufficient for metabolized oral L-arginine intake (Bode-Böger, Boger, Galland, Tsikas, & Frolich, 1998). Training followed a set pattern throughout testing (i.e., morning, 1.5 hr of court-based technical training; midday, 1 hr of physical training in the gym; and afternoon, 2 hr of court-based technical training).
Blood Collection
Blood samples were obtained at baseline on the fourth morning of each treatment before breakfast. From the antecubital vein 2 ml of blood were collected in Vacutainer tubes with heparin (BD Vacutainer, USA) and centrifuged immediately at 3,000 g for 10 min (Heraeus Labofuge, USA); the plasma was stored at -20 °C until analysis.
Measurement of Nitrates
Plasma nitrate concentrations were determined by colorimetric fixing of nitrite with the Griess reagent as described by Moshage, Kok, Huizenga, and Cansen (1995) . Nitrate was reduced to nitrite by incubating 50 µl of plasma in a final volume of 0.5-ml reaction mixture containing 50 mU nitrate reductase, 50 µM NADPH, 5 µM FAD, and 50 mM potassium phosphate buffer pH 7.5 for 20 min at 37 °C. After this, 30 µl of lactate dehydrogenase (0.2 mg/ml in potassium phosphate buffer 0.15 M pH 7.5) and 30 µl of sodium pyruvate 0.2 M were added, and incubation was continued for 5 additional min at 37 °C to oxidize the remaining NADPH. Finally, the samples were deproteinized by adding 30 µl of 300 g/L zinc sulfate, stored at 4 °C for 15 min, and centrifuged at 15,000 g for 5 min at 4 °C. Then, 500 µl of the supernatants were mixed in Eppendorf tubes with 500 µl of the Griess reagent (1 g/L sulphanilamide and 0.1 g/L N-[1 naphthyl] ethylenediamine in 25 g/L phosphoric acid), and, after incubation for 15 min at room temperature, absorbance at 540 nm was measured in a Shimadzu UV-160 (Kyoto, Japan) spec- Souci, Fachman, & Kraut, 1994. trophotometer. Results were compared with a standard curve with known concentrations of nitrite.
Measurement of Malondialdehyde
Malondialdehyde (MDA) level, an indicator of free-radical generation that increases at the end of lipid peroxidation, was estimated using the method of Santos, Valles, Aznar, and Vilches (1980) . The principle of the method is the spectrophotometric measurement of the color generated by reaction of thiobarbituric acid (TBA) with MDA. For this purpose, 50 µl of plasma samples were mixed with 250 µl of physiological serum, 500 µl of trichloroacetic acid (100% p/v; in HCl 6 N), and 100 µl of TBA 0.12 M (in Tris-HCl 0.26 M, pH 7.0). After incubation for 30 min at 100 °C, 1.1 ml of distilled water was added and centrifugation was performed for 5 min at 3,000 g and 4 °C. Absorbance of the supernatants was measured at 532 nm using a spectrophotometer (Shimadzu UV-160, Kyoto, Japan). The concentration of MDA was calculated by the absorbance coefficient of the MDA-TBA complex.
Treadmill Test
All participants were tested in the afternoon. Incremental treadmill tests (Laufergotest LE/6, Jaeger, Germany) were performed at Stage 4 and were maintained for 4 min at an initial speed of 10 km/hr for 3 athletes and 11 km/hr for the others. Each level was followed by a 2-min rest period, after which the speed was increased by 1 km/hr until all participants reached an intensity corresponding to 85% or 90% of VO 2max or a respiratory quotient of 1. During the last 15 s of Minutes 5, 11, 17, and 23 of effort, [La -] b was measured from the earlobe via the micro method (Lactate Pro LT 1710, Germany). Ventilatory frequency, tidal volume, fraction of O 2 exhaled, fraction of CO 2 exhaled, ventilatory volume, rate of ventilatory exchange, and VO 2 were measured in real time using a breath-bybreath cardiorespiratory analyzer (Jaeger Oxycon Champion, Germany), and heart rate (HR) was registered every 5 s (XtrainerPlus, Polar, Finland).
Statistical Analyses
Results were expressed as M ± SD. To compare cardiovascular, metabolic, and biochemical variables between the diets at different task intensities, a two-way repeated-measures analysis (ANOVA) was carried out. Paired Student's t tests were used when only two measurements were involved. The level of significance was set as p < .05.
Results
The energy and macronutrient composition of the three diets are shown in Table  2 . No significant differences were found in participants' body mass over the duration of the study (CD, 67.7 ± 8.7 kg; Diet 1, 67.8 ± 9.1 kg; and Diet 2, 67.4 ± 9.2 kg). No change was observed in MDA concentrations between treatments (Diet 1, 37.7 ± 3.3 mol/L, and Diet 2, 42.6 ± 3.7 mol/L, vs. CD, 41.3 ± 2.6 mol/L). In addition, no significant difference was found in plasma levels of nitrate (Diet 1, 31.9 ± 7.2 mol/L, and Diet 2, 31.3 ± 7.9 mol/L, vs. CD, 30.4 ± 5.8 mol/L). All results for cardiorespiratory (VO 2 , HR) and metabolic ([La -] b ) variables are displayed in Table 3 . There was no significant difference in VO 2 or HR at any of the time points in the three trials. Blood lactate concentration showed a significant effect at 5 min between CD and Diet 2 (CD, 3.0 ± 0.5 mM, Diet 2, 2.5 ± 0.5 mM; p = .03), but this tendency was not found at higher exercise intensities. 108 ± 6.5 112 ± 6.5 108 ± 3.1 Caloric distribution (g · kg −1 · day −1 ) protein 1.9 ± 0.3 1.9 ± 0.3 2.0 ± 0.3 carbohydrate 5.8 ± 0.9 5.8 ± 0.9 5.7 ± 0.8 fat 1.6 ± 0.2 1.6 ± 0.2 1.6 ± 0.2
Note. Diet 1 = enriched food L-arginine diet; Diet 2 = the same as control but further including oral supplement of L-arginine (5 g 3 times per day). 5 min 3.0 ± 0.5 2.9 ± 0.5 2.5 ± 0.5* 11 min 3.2 ± 0.8 3.0 ± 0.7 3.2 ± 1.0 17 min 4.2 ± 0.9 4.1 ± 0.8 4.3 ± 0.7 23 min 6.0 ± 1.4 5.7 ± 1.3 5.7 ± 0.8 *p < .05 between control diet and Diet 2.
Discussion
Our results suggest that a diet enriched with L-arginine or supplementation at high doses does not improve cardiorespiratory or metabolic parameters in highly trained athletes during an endurance task. Statistically significant differences were found in blood lactate accumulation between CD and Diet 1 at low exercise intensities. This unexpected effect occurred without any changes in the cardiorespiratory and plasma nitrate values, and it disappeared at higher effort intensities. The effects of L-arginine supplementation in [La -] b are controversial. Some studies have found significant decreases in [La -] b and ammonia concentrations using oral combinations of L-arginine and L-aspartate (with the aim of increasing L-arginine absorption) at 3-g/day doses (Burtscher, Brunner, Faulhaber, Hotter, & Likar, 2005) . On the other hand, a more recent analysis of arginine supplementation (6 g/day) in athletes showed no effect on [La -] b during and after intermittent exercise in highly trained judo athletes or any increase in measured metabolites of NO (nitrates and citrulline; Liu et al., in press ), nor did the study by Abel et al. (2005) , which used arginine aspartate supplementation, find a positive effect on exercise economy in athletes.
The bioavailability of L-arginine in the human body depends on the administration route used. Oral L-arginine is absorbed in the small intestine and transported to the liver, where the greater part is taken up to be used in the hepatic urea cycle; however, a small part of dietary L-arginine may pass through the liver and be used for substrate NO production, as animal and human studies using 15 N-labeled L-arginine as a precursor have shown (Böger et al., 2004) . One limiting factor of oral supplements is that the high hepatic activity of the enzyme arginase, which breaks down arginine to urea, is thought to prohibit the release of enterally administered L-arginine to the systemic circulation (Van de Poll, Soeters, Deutz, Fearon, & Dejong, 2004) . Approximately 68% of total dietary L-arginine reaches the blood (Bode-Böger et al., 1998) . The quantity of L-arginine in our control diet was adjusted to the average values of the intake of this amino acid in the general population (Venho et al., 2002) . The L-arginine content of Diet 2 was 9.0 ± 1.1 g/day, similar to that used by Siani et al. (2000) . Diet 3 provided 5.5 ± 0.3 g/day in the diet and 15 g/day in supplement form (approximate total = 20.5 g/day) of L-arginine, which was higher than those reported by Colombani et al. (1999; 15 g/day) , Abel et al. (2005; 5 .7 g/day), and Burtscher et al. (2005; 3 g/day) .
Several studies indicated that dietary supplementation of L-arginine may be effective when endothelial L-arginine-NO metabolism presents an impairment that L-arginine can reverse (Coman, Yaplito-Lee, & Boneh, 2008) . However, in agreement with the current study, certain investigations in sports sciences have reported poor results with L-arginine supplementation in NO metabolism during exercise in athletes (Liu et al., 2008) . Nevertheless, when intravenous infusion of L-arginine was administered (acute dose of 3 g) with the aim of avoiding L-arginine losses during digestion and hepatic catabolism, decreases were found in [La -] b and ammonia associated with endothelial-dependent vasodilation, although no positive effects were found on VO 2 or HR values during endurance exercise at submaximal intensities (Schaefer et al., 2002) .
In our study the homogeneity of nitrate plasmatic levels could be associated with failure to improve exercise-economy variables (HR, VO 2 , and [La -] b ) at submaximal running speeds. The rapid metabolism and short half-life of NO pose a considerable obstacle to its analysis in humans. Some authors have used nitrate and nitrite plasma levels to assess NO bioavailability in vivo, because a relationship has been observed between them (Wu & Morris, 1998) . In the current study the nitrate values in plasma were higher than those reported by other authors in sedentary persons (Brown et al., 2000) , suggesting that highly trained athletes have higher baseline concentrations of NO than the general population, but no increases were achieved with a diet enriched with L-arginine or supplementation of amino acid at high doses compared with the CD.
A fundamentally different way of generating NO in NOS-independent pathways was recently used to investigate NO metabolism in athletes. Larsen, Weitzberg, Lundberg, and Ekblom (2007) reported lower oxygen cost during submaximal work and reduced blood nitrite (NO 2 -) levels without an accompanying increase in plasma lactate, indicating that the energy production had become more efficient because of the intake of sodium nitrate supplementation in amounts achievable through a vegetable-rich diet. These findings open up a new line of research into action mechanisms. The main targets need to be clarified, but the process is likely to involve in vivo reduction of nitrate (NO 3 -) into bioactive nitrogen oxides including NO 2 -and NO. On the other hand, some researchers have observed that L-arginine supplementation has an antioxidant effect in animals (Lin, Yang, Tsai, Huang, & Lee, 2006) . This might be related to NO's positive effect on free-radical-scavenging activity in specific conditions (Fukai et al., 2000) . However, our results did not show significant differences in MDA plasma values between the experimental diets and the CD, probably because the NO end-product concentrations did not differ between the experimental and control conditions. Finally, none of the participants suffered any digestive disorder because of the high intake of L-arginine in Diet 3. Large quantities (up to 25 g/day) have been associated with gastrointestinal dysfunction (Barbul, Lazarou, Efron, Wasserkrug, & Efron, 1990) . Nor did we observe changes in body mass, indicating that the energy intake over the trial period was enough to maintain energy balance (Rankin, 2002) .
In summary, the findings show that a short period of diet enrichment with L-arginine or supplementation at high doses had no effect on either plasma nitrate concentration or on exercise-economy-related parameters in highly trained athletes. Significant differences were found in [La -] b at the 5-min time point between CD and Diet 2, but not at high exercise intensities. Further investigations with intravenous L-arginine infusion or intake of inorganic nitrate-rich foods are required to investigate the effects on NO and exercise economy.
